Genervon Biopharmaceuticals recently announced it has filed a patent application based on data from the Phase 2A clinical trial (GALS001 study, NCT01854294) assessing the company’s product GM604 as a therapy for amyotrophic lateral sclerosis (ALS) and data from a single ALS compassionate patient study (GALS-C). ALS is a…
Researchers at the University of California at San Francisco (UCSF) recently revealed new insights into the pathogenesis of neurodegenerative diseases. The study, published in The Journal of Neuroscience, is entitled “The Progranulin Cleavage Products, Granulins, Exacerbate TDP-43 Toxicity and Increase TDP-43 Levels”. Mutations in…
Chris Rosati, who was diagnosed with amyotrophic lateral sclerosis (ALS) in November 2010, challenged the ALS Association to publicly declare that a cure for the disease will be found in the next six years. In an emotional video addressed to the association’s CEO Barbara Newhouse, Mr. Rosati explained…
In a recent study entitled “Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis – A Population-Based Study” researchers investiagated the link between diabetes and amyotrophic lateral sclerosis, confirming that type 2 diabetes, but not type 1, has a protective role against amyotrophic lateral sclerosis evidenced specially in…
The ALS Association participated in the annual BIO International Convention, which occured between June 15 and 18 in Philadelphia. Over 15,000 leaders from the pharmaceutical and biotech industries joined the convention which provided the association with crucial opportunities to establish partnerships that may further the development of treatments for amyotrophic lateral sclerosis disease (ALS). ALS is a…
The ALS (amyotrophic lateral sclerosis) Association revealed that a team of researchers funded by the Association and led by Dr. Timothy Miller and Dr. Randall Bateman from Washington University in Saint Louis, recently discovered important insights into the ALS-related protein called copper (Cu)/zinc (Zn) superoxide dismutase (SOD1). ALS…
Researchers at CRCHUM and the University of Montreal in Canada discovered a previously unknown link between amyotrophic lateral sclerosis (ALS) neurodegeneration and the immune system. The study was recently published in the journal Nature Communications and is entitled “Neurodegeneration in C. elegans models…
Cytokinetics, a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics, and The ALS Association recently announced a collaboration in which Cytokinetics will provide Platinum Level Sponsorship and Gold Level Sponsorship of the National Walks to Defeat ALS for ALS Association Golden West Chapter…
Dr. Ivan Dikic at Goethe University, Frankfurt, Germany has been involved in two groundbreaking studies focusing on molecular details underlying neurodegenerative diseases. The studies were conducted by international research teams and were recently published in the journals Nature Neuroscience – “Haploinsufficiency of TBK1 causes familial…
A new study recently published in the journal PNAS revealed that a new cellular mechanism involving a key protein called hUPF1 can be exploited as a therapeutic strategy for amyotrophic lateral sclerosis (ALS). The study is entitled “Amelioration of toxicity in neuronal models of…
Get regular updates to your inbox.
